natgillin/translations-raw huggingface dataset:
The tablets are swallowed whole and can be taken with or without food or drink.
Lahko se jemljejo sočasno s hrano in pijačo ali brez njiju.
Embryo-foetal development studies in mice and rats showed no evidence of a teratogenic effect at exposure levels 4-fold and 6-fold, respectively, those expected in humans.
Študije razvoja zarodka/plodu pri miših in podganah niso pokazale znakov teratogenega delovanja pri izpostavljenosti, ki je bila 4- oziroma 6-krat večja od pričakovane stopnje izpostavljenosti pri človeku.
The potential for tedizolid or tedizolid phosphate to inhibit transport of probe substrates of important drug uptake (OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2) and efflux transporters (P-gp and BCRP) was tested in vitro.
In vitro so testirali potencial tedizolida ali tedizolid fosfata za zaviranje transporta preiskovanih substratov pomembnih prenašalcev za privzem zdravil (OAT1, OAT3, OATP1B1, OATP1B3, OCT1 in OCT2) in efluksnih prenašalcev (P-gp in BCRP).
What Sivextro is and what it is used for What you need to know before you are given Sivextro How you will be given Sivextro Possible side effects
Kaj je zdravilo Sivextro in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Sivextro Kako boste prejeli zdravilo Sivextro Možni neželeni učinki
Sivextro is incompatible with any solutions containing divalent cations (e.g., Ca
Zdravilo Sivextro je inkompatibilno z vsemi raztopinami, ki vsebujejo dvovalentne katione (npr. Ca
Table 1 Frequency of adverse reactions by System Organ Class in pooled Phase 3 comparative clinical studies
Preglednica 1 Pogostnost neželenih učinkov po organskih sistemih v združenih primerjalnih kliničnih študijah 3. faze
In a mouse thigh infection model of S. aureus, the antibacterial activity of tedizolid was reduced in the absence of granulocytes.
Pri mišjem modelu okužbe stegna z bakterijo S. aureus se je protibakterijsko delovanje tedizolida zmanjšalo v odsotnosti granulocitov.
Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1).
Zdravilo Sivextro je indicirano za zdravljenje akutnih bakterijskih okužb kože in mehkih tkiv (ABSSSI - acute bacterial skin and skin structure infections) pri odraslih (glejte poglavji 4.4 in 5.1).
• sulfasalazine (used to treat inflammatory bowel diseases)
• sulfasalazin (za zdravljenje vnetnih črevesnih bolezni)
Do not shake the bag.
Infuzijske vrečke ne stresajte.
Other medicines and Sivextro
Druga zdravila in zdravilo Sivextro
If you stop taking Sivextro
Če ste prenehali jemati zdravilo Sivextro
• Acid reflux disease (heartburn, pain or difficulty swallowing), flatulence/passing wind
• bolezen refluksa kisline (zgaga, bolečine ali težave pri požiranju), napenjanje/vetrovi
Tedizolid is excreted in the breast milk of rats (see section 5.3).
Tedizolid se pri podganah izloča v mleko (glejte poglavje 5.3).
Do not use this medicine after the expiry date which is stated on the carton or blister label after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, pretisnem omotu ali nalepki poleg oznake "EXP".
The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis.
Protibakterijsko delovanje tedizolida poteka preko vezave na podenoto 50S bakterijskega ribosoma, kar zavre sintezo beljakovin.
• a low white blood cell count
• majhno število belih krvnih celic,
Susceptible (≤S) Resistant (R>)
Odporni (R >)
Lactic acidosis has not been reported in patients treated with tedizolid phosphate at the recommended treatment duration of 6 days.
O laktacidozi niso poročali pri bolnikih, ki so se zdravili s tedizolid fosfatom v priporočenem obdobju 6 dni.
Tedizolid phosphate had no adverse effects on the fertility or reproductive performance of male rats, including spermatogenesis, at oral doses up to the maximum tested dose of 50 mg/kg/day, or adult female rats at oral doses up to the maximum tested dose of 15 mg/kg/day.
Tedizolid fosfat ni imel škodljivih učinkov na plodnost ali sposobnost razmnoževanja podganjih samcev, niti na spermatogenezo, pri peroralnih odmerkih do največjega preskušanega odmerka 50 mg/kg/dan, ali odraslih podganjih samic pri peroralnih odmerkih do največjega preskušanega odmerka 15 mg/kg/dan.
In a 1-month immunotoxicology study in rats, repeated oral dosing of tedizolid phosphate was shown to significantly reduce splenic B cells and T cells and reduce plasma IgG titers.
Enomesečna imunotoksikološka študija na podganah je pokazala, da ponavljajoči peroralni odmerki tedizolid fosfata pomembno zmanjšajo vranične celice B in celice T ter zmanjšajo plazemske titre IgG.
• loss of sensitivity in your hands or feet (such as numbness, prickling/tingling, or sharp pains)
• izgubo občutljivosti v dlaneh ali stopalih (kot so otrplost, zbadanje/mravljinčenje ali ostre bolečine),
No dose adjustment is necessary for co-administered CYP3A4 substrates during treatment with Sivextro.
Prilagoditev odmerkov sočasno uporabljenih substratov CYP3A4 med zdravljenjem z zdravilom Sivextro ni potrebna.
Tedizolid is generally not active against Gram-negative bacteria.
Tedizolid običajno ne deluje proti gramnegativnim bakterijam.
Tedizolid is eliminated in excreta, primarily as a non-circulating sulfate conjugate.
Tedizolid se izloča s telesnimi izločki, zlasti v obliki sulfatnega konjugata, ki ni prisoten v obtoku.
Patients should not take a double dose to compensate for a missed dose.
Bolnik ne sme prejeti dvojnega odmerka, da bi nadomestil izpuščeni odmerek.
• Abscess (swollen, pus-filled lump)
• absces (otečena zatrdlina, napolnjena z gnojem)
The mean Cmax and AUC0-∞ for oral or IV administration of tedizolid phosphate 200 mg were similar in adolescent and in healthy adult subjects.
Povprečni vrednosti Cmax in AUC0-∞ po peroralni ali intravenski uporabi tedizolid fosfata v odmerku 200 mg sta bili podobni pri mladostnikih in zdravih odraslih.
Lactic acidosis has been reported with the use of another member of the oxazolidinone class.
O laktacidozi so poročali pri uporabi drugega zdravila iz skupine oksazolidinonov.
These effects occurred at plasma tedizolid exposure levels (AUC) ≥3-fold greater than the expected human plasma exposure associated with the therapeutic dose.
Ti učinki so se pojavili pri plazemski izpostavljenosti tedizolidu (AUC), ki je bila ≥ 3-krat večja od pričakovane plazemske izpostavljenosti, povezane s terapevtskim odmerkom pri človeku.
Tedizolid is primarily active against Gram-positive bacteria.
Tedizolid deluje primarno proti grampozitivnim bakterijam.
Blood and lymphatic system disorders
Bolezni krvi in limfatičnega sistema limfadenopatija
No clinically relevant interactions are expected to occur with these transporters, with the administration of the parenteral formulation.
Pri teh prenašalcih klinično pomembnega medsebojnega delovanja, pri uporabi parenteralne oblike zdravila, ni pričakovati.
No clinically relevant interactions are expected to occur with these transporters, with the exception of BCRP.
Pri teh prenašalcih, razen pri prenašalcu BCRP, klinično pomembnega medsebojnega delovanja ni pričakovati.
Foetal developmental effects occurring in mice in the absence of maternal toxicity included reduced foetal weights and an increased incidence of costal cartilage fusion (an exacerbation of the normal genetic predisposition to sternal variations in the CD-1 strain of mice) at the high dose of 25 mg/kg/day (4-fold the estimated human exposure level based on AUCs).
Med učinki na razvoj plodu, ki so se pojavljali pri miših v odsotnosti toksičnosti za mater, sta zmanjšana masa plodu in povečana pojavnost fuzije rebrnega hrustanca (poslabšanje normalne genetske nagnjenosti k variacijam prsnice pri mišjem sevu CD-1) pri velikem odmerku 25 mg/kg/dan (4-kratnik ocenjene ravni izpostavljenosti pri človeku, ki temelji na vrednostih AUC).
Acute bacterial skin and skin structure infections
Akutne bakterijske okužbe kože in mehkih tkiv
Haemodialysis does not result in meaningful removal of tedizolid from systemic circulation, as assessed in subjects with endstage renal disease (eGFR <15 mL/min).
Hemodializa ne odstrani pomembne količine tedizolida iz sistemskega krvnega obtoka, kar so ocenili pri preiskovancih s končno odpovedjo ledvic (eGFR < 15 ml/min).
Two placebo-controlled crossover studies were conducted to assess the potential of 200 mg oral tedizolid phosphate at steady state to enhance pressor responses to pseudoephedrine and tyramine in healthy individuals.
Opravili so dve s placebom nadzorovani navzkrižni študiji za oceno potenciala 200 mg peroralnega odmerka tedizolid fosfata, da v stanju dinamičnega ravnovesja poveča presorne odzive na psevdoefedrin in tiramin pri zdravih posameznikih.
Sivextro is an antibiotic that contains the active substance tedizolid phosphate.
Zdravilo Sivextro je antibiotik, ki vsebuje učinkovino tedizolid fosfat.
Sivextro must be reconstituted with water for injections and subsequently diluted in 250 mL of 0.9% sodium chloride for infusion.
Zdravilo Sivextro je treba rekonstituirati z vodo za injekcije in nato razredčiti v 250 ml 0,9-odstotne raztopine natrijevega klorida za injiciranje.
Spontaneous reports of serotonin syndrome associated with the co-administration of another member of the oxazolidinone class together with serotonergic agents have been reported (see section 4.5).
Prejeta so bila spontana poročila o serotoninskem sindromu, povezanem s sočasno uporabo drugega zdravila iz skupine oksazolidinonov s serotoninergičnimi zdravili (glejte poglavje 4.5).
These effects showed evidence of reversibility and occurred at plasma tedizolid exposure levels (AUC) ≥6-fold greater than the plasma exposure associated with the human therapeutic dose.
Ti učinki so kazali znake reverzibilnosti in so se pojavili pri plazemski izpostavljenosti tedizolidu (AUC), ki je bila ≥ 6-krat večja od plazemske izpostavljenosti, povezane s terapevtskim odmerkom pri človeku.
The contents of the vial should be reconstituted with 4 mL of water for injections, and be swirled gently until the powder has dissolved entirely.
Vsebino viale je treba rekonstituirati s 4 ml vode za injekcije in vialo nežno obračati, dokler se prašek popolnoma ne raztopi.
Peak concentrations (Cmax) of tedizolid are reduced by approximately 26% and delayed by 6 hours when tedizolid phosphate is administered after a high-fat meal relative to fasted, while total exposure (AUC0-∞) is unchanged between fasted and fed conditions.
V primerjavi z odmerjanjem na tešče se najvišje koncentracije (Cmax) tedizolida znižajo za približno 26 % in zakasnijo za 6 ur, če se tedizolid fosfat zaužije po mastnem obroku, medtem ko pri skupni izpostavljenosti (AUC0-∞) ni razlike med teščim stanjem in stanjem po obroku.
Following administration of a single 200 mg IV dose of tedizolid phosphate to 8 subjects with severe renal impairment defined as eGFR <30 mL/min, the Cmax was basically unchanged and AUC0-∞ was changed by less than 10% compared to 8 matched healthy subject controls.
Po aplikaciji enkratnega 200 mg intravenskega odmerka tedizolid fosfata 8 preiskovancem s hudo okvaro ledvic, opredeljeno kot eGFR < 30 ml/min, se vrednost Cmax v bistvu ni spremenila, vrednost AUC0-∞ pa se je spremenila za manj kot 10 % v primerjavi z 8 odgovarjajočimi zdravimi preiskovanci iz kontrolne skupine.
Tedizolid phosphate is an oxazolidinone phosphate prodrug.
Tedizolid fosfat je oksazolidinonsko fosfatno predzdravilo.
• Respiratory tract (sinuses, throat and chest) infection
• okužba dihal (sinusov, grla in prsnega koša)
The pharmacokinetics of tedizolid were evaluated in adolescent subjects (12 to 17 years; n=20) following administration of a single oral or IV dose of tedizolid phosphate 200 mg.
Farmakokinetiko tedizolida so ocenili pri mladostnikih (od 12 do 17 let, n = 20) po uporabi enkratnega 200 mg peroralnega ali intravenskega odmerka tedizolid fosfata.
The reconstituted solution must be administered as an intravenous infusion only.
Rekonstituirana raztopina se sme aplicirati samo z intravensko infuzijo.
There is no Phase 3 clinical experience in patients with co-administration of tedizolid phosphate with serotonergic agents such as selective serotonin re-uptake inhibitors [SSRI], serotonin norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants, MAO inhibitors, triptans, and other medicines with potential adrenergic or serotonergic activity.
Kliničnih izkušenj 3. faze ni na voljo pri bolnikih, ki se sočasno zdravijo s tedizolid fosfatom in serotoninergičnimi zdravili, kot so selektivni zaviralci ponovnega privzema serotonina [SSRI], zaviralci ponovnega privzema serotonina in noradrenalina (SNRI), triciklični antidepresivi, zaviralci MAO, triptani in druga zdravila, ki lahko delujejo adrenergično ali serotoninergično.
Tedizolid is excreted into the milk of lactating rats and the concentrations observed similar to those in maternal plasma.
Pri doječih podganah se tedizolid izloča v mleko v koncentracijah, podobnih koncentracijam v plazmi mater.
This effect is not clinically meaningful, and no dose adjustment for co-administered CYP3A4 substrates is necessary during tedizolid phosphate treatment.
Ta učinek ni klinično pomemben in zato med zdravljenjem s tedizolid fosfatom prilagoditev odmerkov sočasno uporabljenih substratov CYP3A4 ni potrebna.
In Phase 3 studies, subjects taking serotonergic agents including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were excluded.
Preiskovanci, ki so jemali serotoninergična zdravila, vključno z antidepresivi, kot so selektivni zaviralci ponovnega privzema serotonina (SSRI) in triciklični antidepresivi, ter agoniste serotoninskih receptorjev 5-hidroksitriptamina (5-HT1) (triptane), meperidin ali buspiron, so bili iz študij 3. faze izključeni.
Following administration of a single 200 mg oral dose of tedizolid phosphate, the pharmacokinetics of tedizolid are not altered in patients with moderate (n=8) or severe (n=8) hepatic impairment (Child-Pugh Class B and C).
Po zaužitju enkratnega 200 mg peroralnega odmerka tedizolid fosfata se farmakokinetika tedizolida pri bolnikih z zmerno (n = 8) ali hudo (n = 8) okvaro jeter (razred B in C po Child-Pughu) ne spremeni.
These dose levels equate to exposure margins of ≥ 5.3-fold for males and ≥ 4.2-fold for females relative to tedizolid plasma AUC0-24 levels at the human oral therapeutic dose.
Te velikosti odmerkov ustrezajo robu izpostavljenosti, ki je pri moških ≥ 5,3-krat in pri ženskah ≥ 4,2-krat večji v primerjavi s plazemskimi vrednostmi AUC0-24 tedizolida pri peroralnem terapevtskem odmerku pri človeku.
Polyvinyl alcohol Titanium dioxide (E171) Macrogol
Filmska obloga polivinilalkohol titanov dioksid (E171) makrogol smukec rumeni železov oksid (E172)
The Cmax and AUC of tedizolid increased approximately dose proportionally within the single oral dose range of 200 mg to 1,200 mg and across the intravenous dose range of 100 mg to 400 mg. Steady-state concentrations are achieved within 3 days and indicate modest active substance accumulation of approximately 30% following multiple once-daily oral or intravenous administration as predicted by a half-life of approximately 12 hours.
Vrednosti Cmax in AUC tedizolida naraščata približno sorazmerno z odmerkom v razponu enkratnih peroralnih odmerkov od 200 mg do 1.200 mg in v razponu intravenskih odmerkov od 100 mg do 400 mg. Koncentracije v stanju dinamičnega ravnovesja so dosežene v 3 dneh in nakazujejo zmerno, približno 30 % kopičenje učinkovine po večkratnem enkrat dnevnem odmerjanju ali intravenski aplikaciji, kar ustreza pričakovanjem glede na razpolovni čas, ki je približno 12 ur.
• Hot flush or blushing/redness in the face, neck or upper chest
• vročinski oblivi ali zardevanje/rdečica na obrazu, vratu ali zgornjem delu prsnega koša
A special neuropathology study was conducted in pigmented Long Evans rats administered tedizolid phosphate daily for up to 9 months.
Pri pigmentiranih podganah vrste Long Evans so opravili posebno nevropatološko študijo, v kateri so živali do 9 mesecev dnevno prejemale tedizolid fosfat.
Effects of other medicines on Sivextro
Vplivi drugih zdravil na zdravilo Sivextro
It must be administered as an intravenous infusion only.
Zdravilo se sme aplicirati samo z intravensko infuzijo.
Clostridioides difficile associated diarrhoea
Diareja, povezana z bakterijo Clostridioides difficile
The safety and efficacy of tedizolid phosphate when administered for periods longer than 6 days have not been established.
Varnost in učinkovitost tedizolid fosfata pri uporabi, daljši od 6 dni, nista bili dokazani.
Reconstitute the contents of the vial with 4 mL water for injections, and swirl gently until the powder has dissolved entirely.
Vsebino viale rekonstituirajte s 4 ml vode za injekcije in vialo nežno obračajte, dokler se prašek popolnoma ne raztopi.
Peak plasma tedizolid concentrations are achieved within approximately 3 hours after dosing after oral administration of tedizolid phosphate under fasted conditions.
Najvišje koncentracije tedizolida v plazmi so dosežene v približno 3 urah po peroralnem odmerjanju tedizolid fosfata na tešče.
Urine odor abnormal
Bolezni sečil nenormalen vonj urina
• Poor control of diabetes
• slabo urejena sladkorna bolezen
The no observed adverse effect levels (NOAELs) for foetal toxicity in mice (5 mg/kg/day) as well as maternal and foetal toxicity in rats (2.5 mg/kg/day) were associated with tedizolid plasma area under the curve (AUC) values approximately equivalent to the tedizolid AUC value associated with the oral human therapeutic dose.
Ravni, pri katerih ni bilo opaznih neželenih učinkov (NOAEL - no observed adverse effect levels) za toksičnost za plod pri miših (5 mg/kg/dan) ter toksičnost za mater in plod pri podganah (2,5 mg/kg/dan), so bile povezane z vrednostmi površine pod krivuljo plazemske koncentracije (AUC) tedizolida, ki so bile približno enakovredne vrednostim AUC tedizolida pri uporabi peroralnega terapevtskega odmerka pri človeku.
Adverse reactions such as lactic acidosis, anaemia and neuropathy (optic and peripheral) may occur as a result of this inhibition.
Posledica tega zaviranja je lahko pojav neželenih učinkov, kot so laktacidoza, anemija in nevropatija (optična in periferna).
What you need to know before you are given Sivextro
Kaj morate vedeti, preden boste prejeli zdravilo Sivextro
Repeated oral and intravenous dosing of tedizolid phosphate in rats in 1-month and 3-month toxicology studies produced dose- and time-dependent bone marrow hypocellularity (myeloid, erythroid, and megakaryocyte), with associated reduction in circulating RBCs, WBCs, and platelets.
Ponavljajoče se peroralno in intravensko odmerjanje tedizolid fosfata pri podganah v 1-in 3-mesečni toksikološki študiji je povzročilo od odmerka in časa odvisno hipocelularnost kostnega mozga (mieloidne, eritroidne in megakariocitne celice), ki jo je spremljalo zmanjšanje števila eritrocitov, levkocitov in trombocitov v obtoku.
The mean steady state volume of distribution of tedizolid in healthy adults (n=8) following a single intravenous dose of tedizolid phosphate 200 mg ranged from 67 to 80 L.
Povprečni volumen porazdelitve tedizolida v stanju dinamičnega ravnovesja po enkratnem 200 mg intravenskem odmerku tedizolid fosfata pri zdravih odraslih (n = 8) je bil v razponu od 67 do 80 l.
In embryo-foetal studies, tedizolid phosphate was shown to produce foetal developmental toxicities in mice and rats.
V študijah na zarodkih in plodovih je imel tedizolid fosfat škodljive učinke na razvoj plodu pri miših in podganah.
The following adverse reactions have been identified in two comparative pivotal Phase 3 studies with Sivextro (Table 1).
V dveh primerjalnih ključnih študijah 3. faze z zdravilom Sivextro so ugotovili naslednje neželene učinke (preglednica 1).
Type I (10 ml) clear borosilicate tubing glass vial with a siliconised grey chlorobutyl rubber stopper.
10-ml viala iz prozornega borosilikatnega cevastega stekla tipa I s sivim klorobutil silikoniziranim gumijastim zamaškom.
Tedizolid phosphate was negative for genotoxicity in all in vitro assays (bacterial reverse mutation [Ames], Chinese hamster lung [CHL] cell chromosomal aberration) and in all in vivo tests (mouse bone marrow micronucleus, rat liver unscheduled DNA synthesis).
Tedizolid fosfat ni izkazal genotoksičnosti v nobenem preskusu in vitro (bakterijske povratne mutacije [Ames], kromosomske aberacije v pljučnih celicah kitajskega hrčka) in v nobenem preskusu in vivo (mikrojedra v mišjem kostnem mozgu, nenačrtovana sinteza DNK v podganjih jetrnih celicah).
The reconstituted solution will be withdrawn from the vial and added to an infusion bag of 0.9% sodium chloride in the hospital.
V bolnišnici se pripravljena raztopina odvzame iz viale in doda v infuzijsko vrečko z 0,9 % raztopino natrijevega klorida.
Tedizolid is bacteriostatic against enterococci, staphylococci, and streptococci in vitro.
In vitro je tedizolid bakteriostatičen proti enterokokom, stafilokokom in streptokokom.
Serotonergic effects at doses of tedizolid phosphate up to 30-fold above the human equivalent dose did not differ from vehicle control in a mouse model that predicts brain serotonergic activity.
Pri mišjem modelu, ki napoveduje serotoninergično delovanje v možganih, se pri odmerkih tedizolid fosfata, do 30-krat večjih od enakovrednega odmerka pri ljudeh, serotoninergični učinki niso razlikovali od kontrole z vehiklom.
• Dry mouth, constipation, indigestion, pain/discomfort in the belly (abdomen), retching, dry heaving, bright red blood in the stool
• suha usta, zaprtost, prebavne motnje, bolečine/neprijeten občutek v trebuhu, siljenje na bruhanje, sprožanje refleksa bruhanja, svetlo rdeča kri v blatu
• Joint pain, muscle spasms, back pain, neck pain, pain/discomfort in limbs, decrease of grip strength
• bolečine v sklepih, mišični krči, bolečine v hrbtu, bolečine v vratu, bolečine/neprijeten občutek v okončinah, zmanjšanje moči prijema
What you need to know before you take Sivextro
Kaj morate vedeti, preden boste vzeli zdravilo Sivextro
Therefore, orally administered Sivextro can result in inhibition of BCRP at the intestinal level.
Pri peroralni uporabi zdravila Sivextro lahko zato pride do zaviranja BCRP na črevesni ravni.
These events have been observed with another member of the oxazolidinone class when administered over a duration exceeding that recommended for tedizolid phosphate.
Te učinke so opazili pri uporabi drugega zdravila iz skupine oksazolidinonov, ko so ga uporabljali dlje, kot je priporočeno za tedizolid fosfat.
• Fungal infections of skin , mouth and vagina (oral / vaginal thrush)
• glivične okužbe kože, ust in nožnice (ustne/vaginalne "gobice")
Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients treated with another member of the oxazolidinone class and the risk of these effects appeared to be related to the duration of treatment.
O mielosupresiji (vključno z anemijo, levkopenijo, pancitopenijo in trombocitopenijo) so poročali pri bolnikih, ki so se zdravili z drugim zdravilom iz skupine oksazolidinonov.
In ABSSSI, the types of infections treated were confined to cellulitis/erysipelas or major cutaneous abscesses, and wound infections only.
Pri akutnih bakterijskih okužbah kože in mehkih tkiv so bile zdravljene vrste okužb omejene samo na celulitis/šen ali večje kožne abscese in okužbe ran.
What Sivextro looks like and contents of the pack Sivextro is a white to off-white powder for concentrate for solution for infusion in a glass vial.
Zdravilo Sivextro je bel do skoraj bel prašek za koncentrat za raztopino za infundiranje v stekleni viali.
Oral and intravenous tedizolid phosphate is a prodrug that is rapidly converted by phosphatases to tedizolid, the microbiologically active moiety.
Peroralni in intravenski tedizolid fosfat je predzdravilo, ki ga fosfataze hitro pretvorijo v mikrobiološko aktivni tedizolid.
Adrenergic agents
Adrenergične učinkovine